Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Johnson_&_Johnson
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:focus |
autoimmune disease therapies
complex drugs |
| gptkbp:foundedYear |
2001
|
| gptkbp:founder |
gptkb:Robert_Langer
gptkb:Ganesh_Kaundinya gptkb:Ram_Sasisekharan |
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Momenta Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
biosimilars
generic enoxaparin |
| gptkbp:status |
defunct
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:MNTA
|
| gptkbp:website |
https://www.momentapharma.com/
|
| gptkbp:bfsParent |
gptkb:Robert_Langer
|
| gptkbp:bfsLayer |
3
|